- Home
- OLP vs ZURA Comparison
OLP vs ZURA Comparison
Compare OLP & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLP | ZURA |
|---|---|---|
| Founded | 1982 | 2022 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.7M | 455.4M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | OLP | ZURA |
|---|---|---|
| Price | $24.71 | $3.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $26.75 | $13.00 |
| AVG Volume (30 Days) | 42.5K | ★ 830.1K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $82,740,000.00 | N/A |
| Revenue This Year | $11.98 | N/A |
| Revenue Next Year | $3.71 | N/A |
| P/E Ratio | $87.21 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $19.62 | $1.00 |
| 52 Week High | $25.38 | $7.25 |
Technical Indicators
Market Signals| Indicator | OLP | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 69.38 | 32.19 |
| Support Level | $22.36 | $3.33 |
| Resistance Level | N/A | $4.12 |
| Average True Range (ATR) | 0.45 | 0.27 |
| MACD | 0.12 | -0.03 |
| Stochastic Oscillator | 89.67 | 21.15 |
Price Performance
Historical ComparisonAbout OLP One Liberty Properties Inc.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred and two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.